2-(1-甲基环丙基)-1H-苯并咪唑 | 150649-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-(1-甲基环丙基)-1H-苯并咪唑
• 英文名称: 2-(1-methylcyclopropyl)-1H-benzimidazole
• CAS: 150649-19-7
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: XALYOHSTMDJDAO-UHFFFAOYSA-N

物化性质

• 沸点：
  373.5±11.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(1-甲基环丙基)-1H-苯并咪唑 在 氢碘酸 作用下， 以 邻二氯苯 为溶剂， 反应 1.58h， 以82%的产率得到3-甲基-2,3-二氢-1H-吡咯并[1,2-a]苯并咪唑
  参考文献：
  名称：

  Synthesis of 2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazoles via the cyclopropyliminium rearrangement of substituted 2-cyclopropylbenzimidazoles

  摘要：

  2-Cyclopropylbenzimidazole derivatives with various substituents in the small ring undergo cyclopropyliminium rearrangement into 2,3-dihydropyrrolobenzimidazoles substituted at positions 1, 2 or 3. The substrates containing a functional group in position 1 of the cyclopropane ring form products substituted at position 3. Substituents at position 2 in most cases lead to the formation of a mixture of isomers. The reaction can be directed to yield one of the isomers predominantly by varying the solvent polarity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.02.021
• 作为产物：
  描述：

  1-甲基环丙烷-1-甲腈 在 盐酸 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 49.0h， 生成 2-(1-甲基环丙基)-1H-苯并咪唑
  参考文献：
  名称：

  Synthesis of 2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazoles via the cyclopropyliminium rearrangement of substituted 2-cyclopropylbenzimidazoles

  摘要：

  2-Cyclopropylbenzimidazole derivatives with various substituents in the small ring undergo cyclopropyliminium rearrangement into 2,3-dihydropyrrolobenzimidazoles substituted at positions 1, 2 or 3. The substrates containing a functional group in position 1 of the cyclopropane ring form products substituted at position 3. Substituents at position 2 in most cases lead to the formation of a mixture of isomers. The reaction can be directed to yield one of the isomers predominantly by varying the solvent polarity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.02.021

文献信息

• Dibenzooxepin derivative
  申请人：Yamamoto Keisuke

  公开号：US08969345B2

  公开（公告）日：2015-03-03

  A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPARγ agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.

  提供了一种二苯并氧吩衍生物，其通式表示为（I），其中Y为氢原子等，RA为氢原子等，X为式（b3），其中RB为氢原子等，A为式（a18），其中R1为氢原子等，RC和RD相同或不同，且每个为氢原子等，该物质具有PPARγ激动剂活性等，可用作治疗和/或预防2型糖尿病等的治疗剂和/或预防剂等，或其药学上可接受的盐等。
• DIBENZOOXEPIN DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2740730B1

  公开（公告）日：2016-11-16
• US6712262B2
  申请人：——

  公开号：US6712262B2

  公开（公告）日：2004-03-30
• US8969345B2
  申请人：——

  公开号：US8969345B2

  公开（公告）日：2015-03-03
• Synthesis of 2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazoles via the cyclopropyliminium rearrangement of substituted 2-cyclopropylbenzimidazoles
  作者：Rinat F. Salikov、Dmitry N. Platonov、Aleksandr E. Frumkin、Dmitry L. Lipilin、Yury V. Tomilov

  DOI：10.1016/j.tet.2013.02.021

  日期：2013.4

  2-Cyclopropylbenzimidazole derivatives with various substituents in the small ring undergo cyclopropyliminium rearrangement into 2,3-dihydropyrrolobenzimidazoles substituted at positions 1, 2 or 3. The substrates containing a functional group in position 1 of the cyclopropane ring form products substituted at position 3. Substituents at position 2 in most cases lead to the formation of a mixture of isomers. The reaction can be directed to yield one of the isomers predominantly by varying the solvent polarity. (C) 2013 Elsevier Ltd. All rights reserved.